iSERA Lifesciences Limited (formerly known as Covidh Technologies Limited) has submitted newspaper advertisements for its postal ballot notice to BSE Limited in compliance with regulatory requirements. The submission was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Postal Ballot Process Details

The company has initiated a postal ballot process for seeking member approval on specified resolutions. The postal ballot notice dated April 21, 2026 has been circulated to all members of the company for their consideration and voting.

Publication and Accessibility

The postal ballot notice advertisement has been published in leading newspapers to ensure wide dissemination among stakeholders. The company has chosen both English and regional language publications for comprehensive coverage.

Published in:

• Financial Express – April 22, 2026
• Loksatta – April 22, 2026

The postal ballot notice is also accessible on the company's official website at www.covidhtechnologies.com , providing digital access to shareholders and other interested parties.

Company Information

iSERA Lifesciences Limited operates under CIN L72200PN1993PLC252720 and trades with scrip code 534920. The company's registered office is located at Office No. A1-1202, 12th Floor, Boulevard Tower, Phase-2, CTS No. 11, Sadhu Vaswani Chowk, Camp, Pune – 411001.

Regulatory Compliance

The submission demonstrates the company's adherence to regulatory disclosure requirements under SEBI listing regulations. Company Secretary and Compliance Officer Deepakshi, with membership number A76335, has digitally signed the communication to BSE on April 22, 2026 at 13:16:03 +05'30'.

The remote e-voting facility provides shareholders with a convenient mechanism to participate in the decision-making process during the specified voting period extending until May 21, 2026.

iSERA Lifesciences Limited has announced that its Board of Directors will convene on Monday, April 20, 2026, to deliberate on significant corporate matters, including a proposed preferential issue of equity shares. The company, formerly known as Covid Technologies Limited, has formally notified BSE Limited about this scheduled meeting in accordance with regulatory requirements.

Meeting Agenda and Purpose

The primary focus of the Board meeting will be to consider and approve the preferential issue of equity shares on a private placement basis. This corporate action represents a significant capital-raising initiative for the pharmaceutical company. The meeting will also address other business matters, though specific details of additional agenda items have not been disclosed.

Regulatory Compliance Details

The notification was submitted pursuant to Regulation 29(1)(d) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, which mandates prior intimation of Board meetings for specific corporate actions.

Company Information

iSERA Lifesciences Limited operates from its registered office located at Office No. A1-1202, 12th Floor, Boulevard Tower, Phase-2, CTS No. 11, Sadhu Vaswani Chowk, Camp, Pune – 411001. The company maintains its corporate identity under CIN: L72200PN1993PLC252720 and trades on BSE with scrip code 534920.

Authorization and Documentation

The formal communication to BSE was digitally signed by Deepakshi, Company Secretary & Compliance Officer (Membership No.: A76335), on April 15, 2026. The digital signature was authenticated at 17:41:26 +05'30', ensuring proper documentation and compliance with electronic filing requirements.

The preferential issue, if approved, will enable the company to raise capital through private placement, providing strategic flexibility for business expansion and operational requirements. Shareholders and market participants will await the Board's decision following the April 20, 2026 meeting.